Background: Sickle cell disease is a major public health issue in the Democratic Republic of Congo (DRC), but it is still poorly understood by health professionals. The objective of this study was to assess the knowledge and practices of Congolese physicians treating sickle cell disease (SCD), in order to identify the areas for improvement in clinical care. Methods: This was a descriptive observational study conducted among Congolese physicians using a questionnaire. Participants were evaluated using a pre-established answer grid. Results: A total of 460 physicians participated, including 81 women (18%), with an average age of 35 years (range 25–60 years). Most physicians were general practitioners. Although self-assessment of their level of knowledge on SCD was estimated as average to good, less than half of the participants (n = 460; 46%) reported adequate management of vaso-occlusive crises, and only 1% of them had received specific training on SCD. Most physicians reported difficulties both in terms of diagnostic (65%) and management (79%) options of SCD patients. This study also showed that 85% of these physicians did not have access to the diagnostic tools for SCD. Conclusions: Insufficient knowledge on SCD and poor diagnostic and treatment options might contribute to increased morbidity and mortality of patients living in the DRC. Interventions aiming to improve physicians’ knowledge, patient follow-up, and treatment access are needed. Specific training alongside existing programs (HIV, malaria), early diagnosis of the disease, and the creation of patient advocacy groups should be implemented to improve SCD patient care.
INTRODUCTION: L´hydroxyurée est le seul produit dont l´efficacité a été prouvée pour prévenir les complications de la drépanocytose et approuvé par la Food and Drug Administration. Pour pouvoir offrir ce traitement aux patients atteints de drépanocytose, il doit être prescrit, disponible et à un prix abordable. L´objectif de cette étude est de déterminer la disponibilité et le coût de l´hydroxyurée sur le marché en République démocratique du Congo et comparer les deux aspects entre une ville reculée, à savoir Mbujimayi, et une grande ville, à savoir, Lubumbashi. METHODES: il s´agit d´une étude transversale réalisée dans le cadre d´une enquête face-à-face menée du 1er avril au 1er septembre 2017 auprès de 188 pharmacies congolaises. RESULTATS: hydroxyurée était disponible dans 41/188 (22%) pharmacies participantes, mais plus fréquemment dans celles d´une grande ville que dans celles d´une ville reculée (34/96 contre 7/92). La plupart des patients ont reçu une ordonnance médicale (36/41; 88%). Le prix moyen de l´hydroxyurée était de 15 $ (10 $ à 35 $) pour une boîte de 25 gélules; ce prix est supérieur au pouvoir d´achat de la majorité des patients drépanocytaires. L´hydroxyurée reste encore un produit importé de l´Europe, des États-Unis ou d´Asie. CONCLUSION: l´hydroxyurée est l´un des principaux traitements permettant d´améliorer l´évolution de la maladie chez les patients drépanocytaires. Néanmoins, en République Démocratique du Congo, sa disponibilité pourrait être améliorée, en particulier dans une ville reculée, et son prix reste trop élevé pour être payé par la population locale.
INTRODUCTION: La dr?panocytose est tr?s fr?quente en R?publique D?mocratique du Congo (RDC). Cette ?tude ?value le niveau de connaissance et les comportements de familles concern?es ainsi que l?impact de cette maladie dans leur quotidien. METHODES: C?est une ?tude transversale, sur un ?chantillon non al?atoire, men?e du 15 juin au 15 ao?t 2015 aupr?s de 50 familles concern?es par la dr?panocytose ? Mbujimayi en RDC. RESULTATS: Sur 50 familles ?tudi?es, 22 familles avaient plus d?un enfant dr?panocytaire. L??ge m?dian au diagnostic ?tait de 1 an. Le diagnostic ?tait clinique dans 42% (21) des cas. Chaque premier enfant dr?panocytaire faisait en moyenne annuellement 3 crises douloureuses, 4 ?pisodes de fi?vre, recevait 2 transfusions sanguines et ?tait hospitalis? 3 fois. 62% (31) des familles n?avaient pas un revenu mensuel suffisant pour la prise en charge de leur(s) enfant(s), 96% (48) des familles souhaite la cr?ation d?un centre de r?f?rence de prise en charge et 94% (47) acceptent de s?y abonner si le montant annuel est inf?rieur ? 100$.
The management of adolescents living with HIV represents a particular challenge in the global response to HIV. The challenges specific to this age group include difficulties engaging and maintaining them in care, challenges with transition to adult care, and limited therapeutic options for treatment-experienced patients, all of which have been jeopardized by the COVID-19 pandemic. This paper summarizes some of the challenges in managing adolescents living with HIV, as well as some of the most recent and innovative therapeutic approaches in this population.
19 December 2021 in Journal of Medical Case Reports
Background: Sickle cell disease and oculocutaneous albinism are rare autosomal recessive disorders both related to mutations on chromosome 11. The diagnosis of patients suffering from both pathologies is necessary to enable dedicated monitoring of any complications at the ophthalmic and skin level. However, few cases are described in the literature.Case presentation: A 14-month-old Congolese male child affected by oculocutaneous albinism, presented with pallor and jaundice. Blood indices revealed severe hemolytic anemia, which led to the diagnosis of sickle cell disease. The patient received a blood transfusion and close follow-up.Conclusions: The co-inheritance of sickle cell disease and oculocutaneous albinism is a reality in the Democratic Republic of Congo, although it is rarely described. Given the current state of our knowledge, specific surveillance, specifically regarding cutaneous and ophthalmological complications, should be offered in this particular population. To enable this dedicated follow-up, sensitization to screening for sickle cell anemia in albino individuals should be carried out.
INTRODUCTION: The use of antitussives is a crucial issue in pediatrics and can lead to respiratory complications that can affect the prognosis. The objective of this study is to determine the frequency of respiratory complications associated with the use of antitussives in pediatrics in a remote city in the Democratic Republic of Congo. METHODS: this is a cross-sectional retrospective study conducted between January 1, 2017, and December 2022. Patients under 12 years of age with an acute cough were eligible. The parameters studied were treatment with cough suppressants and associated respiratory complications. RESULTS: a total of 218 children suffered from an acute cough. The average age was 11 months 10, and the sex ratio (H/F) was 126/92. In 30% of cases, children were treated with cough suppressants for an average of 7 days before admission. Respiratory complications were observed in 11% (23/218) of cases. For most of these complications, 61% (14 of 23), had received antitussive treatment before hospitalization. Respiratory complications were associated with cough medications (p-value = 0.0012, relative risk (RR) = 3.66, IC90 [1.696; 7,873]). Acute respiratory distress was reported in 87% (20/23) of cases and was associated with the use of cough suppressants (p-value = 0.0065, RR: 3.060, IC90: [1.433; 6,485]). CONCLUSION: the use of antitussives in pediatrics poses a risk of acute respiratory distress in a remote city that does not have sufficient human and material resources for management.